Evidence map›Paper›PMID 37442993›Full record

ArticleBMC medical informatics and decision making2023

Development of a novel drug information provision system for Kampo medicine using natural language processing technology.

Ayako Maeda-Minami, Tetsuhiro Yoshino, Tetsuro Yumoto, Kayoko Sato, Atsunobu Sagara, Kenjiro Inaba, Hidenori Kominato, Takao Kimura, Tetsuya Takishita, Gen Watanabe and 5 more

Open access · goldAbstract read
In one paragraph

Article in BMC medical informatics and decision making, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
0.2field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it, 1 citations in OpenAlex.

  1. Pooled it
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 5 institutions in 1 country.

Ayako Maeda-MinamiFaculty of Pharmaceutical Sciences, Tokyo University of Science, Noda, Yamazaki, Chiba, 2641, Japan. ayako.maeda@rs.tus.ac.jp.
Tetsuhiro YoshinoCenter for Kampo Medicine, Keio University School of Medicine, 35, Shinanomachi, Shinjuku-ku, Tokyo, Japan.
Tetsuro YumotoHoshi University, 2-4-41 Ebara, Shinagawa-ku, Tokyo, Japan.
Kayoko SatoHoshi University, 2-4-41 Ebara, Shinagawa-ku, Tokyo, Japan.
Atsunobu SagaraHoshi University, 2-4-41 Ebara, Shinagawa-ku, Tokyo, Japan.
Kenjiro InabaDepartment of Pharmacy, General Sagami Kosei Hospital, Oyama, Chuou-ku, Sagami, Kanagawa, 3429, Japan.
Hidenori KominatoI&H Co. Ltd, 1-18 Oomasuchou, Ashiya, Hyogo, Japan.
Takao KimuraKimura Information Technology Co. Ltd, 6-1 Oroshihonmachi, Saga, Saga, Japan.
Tetsuya TakishitaKimura Information Technology Co. Ltd, 6-1 Oroshihonmachi, Saga, Saga, Japan.
Gen WatanabeKimura Information Technology Co. Ltd, 6-1 Oroshihonmachi, Saga, Saga, Japan.
Tomonori NakamuraDivision of Pharmaceutical Care Sciences, Center for Social Pharmacy and Pharmaceutical Care Science, Faculty of Pharmacy, Keio University, 1-5-30, Shibakoen, Minato-ku, Tokyo, Japan.
Yasunari ManoFaculty of Pharmaceutical Sciences, Tokyo University of Science, Noda, Yamazaki, Chiba, 2641, Japan.
Yuko HoribaCenter for Kampo Medicine, Keio University School of Medicine, 35, Shinanomachi, Shinjuku-ku, Tokyo, Japan.
Kenji WatanabeCenter for Kampo Medicine, Keio University School of Medicine, 35, Shinanomachi, Shinjuku-ku, Tokyo, Japan.
Junzo KameiJuntendo Advanced Research Institute for Health Science, Juntendo University, 2-1-1, Hongou, Bunkyo-ku, Tokyo, Japan.
Keio University · JPHoshi University · JPTokyo University of Science · JPJuntendo University · JPSaga-Ken Medical Centre Koseikan · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundKampo medicine is widely used in Japan; however, most physicians and pharmacists have insufficient knowledge and experience in it. Although a chatbot-style system using machine learning and natural language processing has been used in some clinical settings and proven useful, the system developed specifically for the Japanese language using this method has not been validated by research. The purpose of this study is to develop a novel drug information provision system for Kampo medicines using a natural language classifier® (NLC®) based on IBM Watson.

methodsThe target Kampo formulas were 33 formulas listed in the 17th revision of the Japanese Pharmacopoeia. The information included in the system comes from the package inserts of Kampo medicines, Manuals for Management of Individual Serious Adverse Drug Reactions, and data on off-label usage. The system developed in this study classifies questions about the drug information of Kampo formulas input by natural language into preset questions and outputs preset answers for the questions. The system uses morphological analysis, synonym conversion by thesaurus, and NLC®. We fine-tuned the information registered into NLC® and increased the thesaurus. To validate the system, 900 validation questions were provided by six pharmacists who were classified into high or low levels of knowledge and experience of Kampo medicines and three pharmacy students.

resultsThe precision, recall, and F-measure of the system performance were 0.986, 0.915, and 0.949, respectively. The results were stable even with differences in the amount of expertise of the question authors.

conclusionsWe developed a system using natural language classification that can give appropriate answers to most of the validation questions.

Indexed as

Medicine, KampoPhysiciansHumansJapanNatural Language ProcessingPharmacistsTechnologyChatbotsConversational agentsDrug information provision systemKampo medicineNatural language processingQuestion-answering

Identifiers

PMID37442993
PMCPMC10347708
OpenAlexW4384204078

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.